RxDoctor Payments Data

Mark Izzo, MD

Interventional Cardiology · Erie, PANPI 1811975584

Payments from drug & device makers

$42,941in general payments, 2019–2025

Across 156 payments — averaging $275.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$20K
  • E.r. Squibb & Sons, L.L.C.$15K
  • Edwards Lifesciences$2K
  • Abiomed$2K
  • Novartis$1K
  • Boston Scientific$843
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$6,469100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,941 in reported general payments places this provider in the 70th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$98,083
Medicare patients
464
Services billed
822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan435$505,561
EliquisApixaban198$209,409
FarxigaDapagliflozin Propanediol195$182,736
Repatha SureclickEvolocumab141$140,342
XareltoRivaroxaban114$128,741
JardianceEmpagliflozin105$117,979
Ranolazine ErRanolazine350$39,417
Praluent PenAlirocumab19$15,771
BrilintaTicagrelor15$8,392
Atorvastatin Calcium494$5,346
Metoprolol Succinate536$4,944
Ezetimibe183$3,625
Bumetanide83$3,514
Metoprolol Tartrate311$2,082
Carvedilol219$2,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,037$505,561435 claims
PfizerEliquis$43$209,409198 claims
AstraZenecaFarxiga, Brilinta$20,385$191,128210 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →